胸腺肽联合抗结核药物治疗耐多药肺结核临床效果评价.docVIP

胸腺肽联合抗结核药物治疗耐多药肺结核临床效果评价 　　[摘要]目的 探讨耐多药肺结核予以胸腺肽联合抗结核药物治疗的临床效果。方法 选取2015年12月7日～2017年1月1日沈阳市胸科医院收治的68例耐多药肺结核患者作为研究对象。根据完全随机原则将其分为两组，每组各34例。对照组患者采取常规抗结核药物治疗，观察组患者在此基础上加用胸腺肽治疗。观察两组患者的生化指标、痰菌转阴、空洞闭合及不良事件发生情况。结果 两组患者治疗前后的血红蛋白、谷丙转氨酶、尿素氮水平比较，差异均无统计学意义（P0.05）。观察组患者治疗3个月、半年及疗程结束的痰菌转阴率（52.94%、64.71%、73.53%）均高于对照组（29.41%、38.24%、44.12%），差异有统计学意义（P0.05）。两组患者的不良事件发生率比较，差异无统计学意义（P0.05）。结论 在耐多药肺结核治疗中，抗结核药物联合胸腺肽治疗效果较佳，可显著缓解病情，促进疾病康复，且安全性较高。 　　[关键词]耐多药肺结核；胸腺肽；抗结核药物 　　[中?D分类号] R521 [文献标识码] A [文章编号] 1674-4721（2018）3（b）-0142-04 　　Clinical effect evaluation of Thymosin combined with antituberculosis drugs in the treatment of multi-drug resistant tuberculosis 　　XU Jiang-tao1 HU Xiao-hong2 WANG Yu-min3 　　1.Shenyang Chest Hospital，Liaoning Province，Shenyang 110044，China；2.Department of Cadre，Northern Theater Command Air Force Hospital，Liaoning Province，Shenyang 110015，China；3.Medical Team，Security Department，the Fifth Brigade of Air Force Information，Northern Theater Command，Liaoning Province，Shenyang 110015，China 　　[Abstract]Objective To investigate the therapeutic effect of Thymosin combined with antituberculosis drugs in the treatment of multi-drug resistant tuberculosis.Methods From December 7，2015 to January 1，2017，68 patients with multi-drug resistant tuberculosis treated in Shenyang Chest Hospital were selected as subjects.They were evenly divided into two groups according to the complete random principle，34 cases in each group.according to different treatment methods.In the control group，conventional anti-tuberculosis drug treatment was used，while on the basis of the control group，Thymosin was added in the observation group.The biochemical indicators，sputum negative conversion，cavity closure and occurrence of adverse events were observed.Results There was no statistically significant difference between the two groups of patients before and after treatment of hemoglobin，alanine transaminase and urea nitrogen levels （P0.05）.Treatment for 3 months，treatment for half year and end